MLchartDataset catalogue

Cusatuzumab

Term · Oncology and biomedicine · MLC-T-ONC-012837

A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.

Table 1. Record
IdentifierMLC-T-ONC-012837
FieldOncology and biomedicine
Synonymsanti-CD70 monoclonal antibody ARGX-110
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012837",
  "term": "Cusatuzumab",
  "field": "Oncology and biomedicine",
  "definition": "A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.",
  "synonyms": [
    "anti-CD70 monoclonal antibody ARGX-110"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cusatuzumab/"
}

Record 5,519 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.